Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 401–500 of 1,008
Bakrania, P., Hall, G., Bouter, Y., Bouter, C., Beindorff, N., Cowan, R. H., Davies, S. L., Price, J., Mpamhanga, C., Love, E. A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01385-7 · Cited by 35
Spoleti, E., Krashia, P., Barbera, L. L., Nobili, A., Lupaşcu, C. A., Giacalone, E., Keller, F., Migliore, M., Renzi, M., & D’Amelio, M. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113969 · Cited by 31
Vascular cognitive impairment and dementia: An early career researcher perspective
Silva, N. C. B. S., Bracko, O., Nelson, A. R., de Oliveira, F. F., Robison, L. S., Shaaban, C. E., Hainsworth, A. H., & Price, B. R. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12310 · Cited by 38
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition
Ozlen, H., Binette, A. P., Köbe, T., Meyer, P., Gonneaud, J., St‐Onge, F., Provost, K., Soucy, J., Rosa‐Neto, P., Breitner, J. C. S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2442 · Cited by 35
Caramelli, B., Yu, P. C., Cardozo, F. A. M., Magalhães, I. R., Spera, R. R., Amado, D. K., Escalante-Rojas, M. C., Gualandro, D. M., Calderaro, D., Tavares, C. A. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02563-2 · Cited by 34
Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae
Rother, C., Uhlmann, R. E., Müller, S. A., Schelle, J., Skodras, A., Obermüller, U., Häsler, L. M., Lambert, M., Baumann, F., Xu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34538-5 · Cited by 28
Beyond Vision: A View from Eye to Alzheimer's Disease and Dementia
Zheng, C., Zeng, R., Wu, G., Hu, Y., & Yu, H. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.118 · Cited by 30
“Additionally, many clinical trials have been undertaken and some promising agents, such as lecanemab and donanemab, were supposed to contribute to slowing the cognition decline in patients with early symptomatic AD (88-91).”
Salemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28
“%) were reported requiring hospitalization due to ARIA-E [76].”
BackgroundMethodPan, F., Huang, Y., Cai, X., Wang, Y., Guan, Y., Deng, J., Yang, D., Zhu, J., Zhao, Y., Xie, F., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00295-9 · Cited by 27
“A lzheimer ’ s disease becomes an ever-growing burden on public health 1 . effective Most existing treatments and ongoing clinical trials of innovative medicines all appeared more on MCI or early Alzheimer ’ s disease patients, especially those who had abnormal levels of brain A β 2,3 .”
Tosun, D., Yardibi, O., Benzinger, T. L. S., Kukull, W. A., Masters, C. L., Perrin, R. J., Weiner, M. W., Simen, A. A., Schwarz, A. J., & Initiative, A. D. N. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13447 · Cited by 32
Sato, S., Hatakeyama, N., Fujikoshi, S., Katayama, S., Katagiri, H., & Sims, J. R. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00604-x · Cited by 30
Self-citationPanza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 30
“Donanemab [65], lecanemab [12], and aducanumab [66] reported a decline in amyloid burden respectively of 85%, 55% and 27% relative to placebo.”
Antonioni, A., Raho, E. M., Lorenzo, F. D., Manzoli, L., Flacco, M. E., & Koch, G. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12996-3 · Cited by 36
“As a result, neuropathological biomarkers have become essential not only for confirming diagnoses but also for assessing eligibility for clinical trials [39–41].”
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 38
“Reduction in the levels of AD biomarkers (such as A β plaques and plasma p-Tau217) was observed during clinical trials [360].”
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
Rodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Abdelnour, C., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J. P. M., Pilotto, A., Rongve, A., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00299-w · Cited by 29
“The Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) has been validated for use in both AD and PD and has been used as a primary outcome in trials of potential DMTs [181].”
MethodThe Current Landscape of Prevention Trials in Dementia
Lee, J., Howard, R. S., & Schneider, L. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01236-5 · Cited by 33
Julku, U. H., Xiong, M., Wik, E., Roshanbin, S., Sehlin, D., & Syvänen, S. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00398-w · Cited by 28
“Additionally, three anti-Aβ antibodies (lecanemab [3, 4], gantenerumab [5, 6] and donanemab [7, 8]) are presently studied in phase III clinical trials.”
BackgroundDevelopment, initial validation, and application of a visual read method for [ 18 F]MK‐6240 tau PET
Shuping, J., Matthews, D. C., Adamczuk, K., Scott, D., Rowe, C. C., Kreisl, W. C., Johnson, S. C., Lukic, A. S., Johnson, K. A., Rosa‐Neto, P., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12372 · Cited by 37
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
Gouilly, D., Rafiq, M., Nogueira, L., Salabert, A., Payoux, P., Péran, P., & Pariente, J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.006 · Cited by 35
Devi, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1213968 · Cited by 30
Cao, Y., Yu, F., Lyu, Y., & Lu, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1034243 · Cited by 26
“Despite mixed secondary outcomes, donanemab has a better composite score for cognition and ability to perform activities of daily living than placebo (35).”
BackgroundInfluentialCummings, J. L. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12411 · Cited by 32
Jaye, S., Sandau, U. S., & Saugstad, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1378576 · Cited by 26
“A β burden can be decreased in some patients, but progression is not completely halted (Sevigny et al., 2016; Mintun et al., 2021; Swanson et al., 2021; Budd Haeberlein et al., 2022) suggesting that targeting A β is not sufficient to significantly alter other molecular pathways involved in later…”
Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease
Inamdar, A., Gurupadayya, B., Halagali, P., Nandakumar, S., Pathak, R., Singh, H., & Sharma, H. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128344571241018154506 · Cited by 36
Fulcher, J. M., Ives, A. N., Tasaki, S., Kelly, S. S., Williams, S., Fillmore, T., Zhou, M., Moore, R., Qian, W., Paša‐Tolić, L., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100983 · Cited by 27
“…pyro-Glu A β pE3-42 based on having the strongest correlation with pathology, which agrees with the rationale behind the development of donanemab (123), the low abundance of pyro-Glu AB pE3-x (relative to other A β proteoforms identi fi ed in our study) suggests looking for other anti-amyloid…”
Rombouts, F. J. R., Kusakabe, K., Alexander, R., Austin, N. E., Borghys, H., Cleyn, M. A. J. D., Dhuyvetter, D., Gijsen, H. J. M., Hrupka, B. J., Jacobs, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00935 · Cited by 27
Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data
Høilund‐Carlsen, P. F., & Alavi, A. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215275 · Cited by 26
Aducanumab: A new hope in Alzheimer's disease
Ali, R., Gupta, G. D., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100039 · Cited by 37
Delrieu, J., Bateman, R. J., Touchon, J., Sabbagh, M., & Cummings, J. L. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.48 · Cited by 30
“Donanemab (13) TRAILBLAZER ALZ Prodromal to mild AD 59.”
BackgroundInfluentialHook, G., Kindy, M. S., & HOOK, V. Y. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221005 · Cited by 28
Planche, V., & Villain, N. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0815 · Cited by 27
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Kepp, K. P., Castellani, R. J., Perry, G. L., Alavi, A. A., & Barrio, J. R. (2023) · Diagnostics · doi:10.3390/diagnostics13132254 · Cited by 30
“, 2021 [11] TRAILBLAZER-ALZ Prodromal AD (MCI incl.”
BackgroundInfluentialAmyloid-lowering monoclonal antibodies for the treatment of early Alzheimer’s disease
Leisher, S., Bohorquez, A., Gay, M., Garcia, V., Jones, R., Baldaranov, D., & Rafii, M. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01021-8 · Cited by 26
“Based on the late-stage results, the amyloid-lowering monoclonal antibodies used in the early AD stage of the AD continuum slow cognitive decline by approximately 25–30% over 18 months [20, 22, 25].”
BackgroundAnti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 26
Aducanumab in Alzheimer’s Disease: A Critical Update
Ashique, S., Sirohi, E., Kumar, S., Rihan, M., Mishra, N., Bhatt, S., Gautam, R. K., Singh, S. K., Gupta, G., Chellappan, D. K., et al. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230727103553 · Cited by 28
Jin, M., Wang, S., Gao, X., Zou, Z., Hirotsune, S., & Sun, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382231 · Cited by 28
“In addition to aducanumab and lecanemab, some other monoclonal antibodies, A B Review such as donanemab, are currently waiting for approval (Mintun et al., 2021; Rashad et al., 2022).”
BackgroundVandeVrede, L. A., Joie, R. L., Horiki, S., Mundada, N. S., KOESTLER, M. E., Hwang, J., Ljubenkov, P. A., Rojas, J. C., Rabinovici, G. D., Boxer, A. L., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02631-8 · Cited by 28
“Aducanumab is one example of a class of amyloid-targeting antibodies proposed as treatment for early AD [4, 9], but few clinicopathological studies are available from patients given these treatments.”
BackgroundNeuronal microstructural changes in the human brain are associated with neurocognitive aging
Singh, K., Barsoum, S., Schilling, K. G., An, Y., Ferrucci, L., & Benjamini, D. (2024) · Aging Cell · doi:10.1111/acel.14166 · Cited by 23
“…of developing a sensitive MRI framework to assess age related microstructural changes in GM has been high-lighted by recent anti- amyloid-β clinical trials that showed increased GM atrophy was observed despite evidence of target engagement and a slowdown in cognitive decline (Mintun et al., 2021).”
A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer’s Disease
Kashif, M., Sivaprakasam, P., Vijendra, P. D., Waseem, M., & Pandurangan, A. K. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128264355231121064704 · Cited by 30
How donanemab data address the coverage with evidence development questions
Klein, E. G., Schroeder, K. M., Wessels, A. M., Phipps, A., Japha, M., Schilling, T., & Zimmer, J. A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13700 · Cited by 25
“11,41,42 TherateofARIAinTRAILBLAZER-ALZ2 11 was similar to the Phase 2 trial, 9 and ARIA events (amyloid-related imaging abnormalities of edema/effusions [ARIA-E] and ARIA-H) for the a Patient-reported quality of life was assessed in a subset of patients in TRAILBLAZER-ALZ 2 using the QOL-AD…”
BackgroundMethodSelf-citationLevak, N., Lehtisalo, J., Thunborg, C., Westman, E., Andersen, P., Andrieu, S., Broersen, L. M., Coley, N., Hartmann, T., Irving, G. F., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01522-8 · Cited by 31
“Although there have been encouraging advancements in the use of new anti-amyloid drugs [3–5], these disease modifying drugs for AD are not suitable for everyone.”
BackgroundVerberk, I. M. W., Jutte, J., Kingma, M. Y., Vigneswaran, S., Gouda, M., van Engelen, M. E., Alcolea, D. A., Arranz, J., Fortea, J., Lleó, A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14088 · Cited by 26
α-Synuclein pathology and mitochondrial dysfunction: Toxic partners in Parkinson's disease
Mingo, Y. B., Galvis, M. L. E., & Henderson, M. X. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106889 · Cited by 31
“Immunotherapy, once thought unviable for the brain, has surged in recent years due to the demonstrated ability for anti-amyloid β antibodies to clear plaques in Alzheimer ’ s disease subjects (Riederer, 2021; Sims et al., 2023; Budd Haeberlein et al., 2022; Golde and Levey, 2023).”
Lan, G., Wang, M., González‐Ortiz, F., Zhang, L., Li, A., Li, B., Jiang, M., Yang, J., Chen, X., Shi, D., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00904-3 · Cited by 38
“It is also crucial because the beneficial effects of anti-amyloid immunotherapies were lower in patients with clinical AD with high tau pathology 5,45,46 .”
Massetti, N., Russo, M., Franciotti, R., Nardini, D., Mandolini, G. M., Granzotto, A., Bomba, M., Pizzi, S. D., Mosca, A., Scherer, R., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210573 · Cited by 28
“On the other hand, a growing body of evidence shows that prevention strategies may delay AD onset and progression [13–21].”
Vukicevic, M., Fiorini, E., Siegert, S., Carpintero, R., Rincón-Restrepo, M., López-Deber, M. P., Piot, N., Ayer, M., Rentero, I., Babolin, C., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac022 · Cited by 31
“This notion is now receiving clinical validation as a proof of concept study involving passive immunization with a mAb, Donanemab (LY3002813), specific for pyroglutamate Abeta, has demonstrated encouraging clinical results in a recently published Phase 2 clinical study.(10)”
Mattke, S., Filho, O. C. D. S., Hanson, M., Mateus, E. F., Neto, J. P. R., de Souza, L. C., Schultz, R. R., & Pinto, R. P. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12778 · Cited by 28
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
Smith, A. M., Obuchowski, N. A., Foster, N. L., Klein, G., Mozley, P. D., Lammertsma, A. A., Wahl, R. L., Sunderland, J. J., Vanderheyden, J., Benzinger, T. L. S., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264031 · Cited by 26
“The clinical trial of donanemab applied an innovative strategy of using quantitative changes in amyloid PET to decide when individual treatment goals had been achieved and treatment discontinued (4).”
MethodBaazaoui, N., & Iqbal, K. (2022) · Biomolecules · doi:10.3390/biom12101409 · Cited by 30
Siemers, E., Hitchcock, J., Sundell, K. L., Dean, R. A., Jerecic, J., Cline, E. N., Iverson, K., Moore, J. A., Edgar, C. J., Manber, R., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.93 · Cited by 33
“, aducanumab and donanemab, may slow cognitive decline of AD (2, 3).”
BackgroundInfluentialSandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 31
Palaniyandi, T., Kanagavalli, B., Prabhakaran, P., Viswanathan, S., Wahab, M. R. A., Natarajan, S., Moorthy, S. K. K., & Saravanan, K. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.151997 · Cited by 26
Operationalizing the centiloid scale for [ 18 F]florbetapir PET studies on PET/MRI
Coath, W., Marc Modat, A., Cardoso, M. J., Markiewicz, P. J., Lane, C., Parker, T. D., Keshavan, A., Buchanan, S. M., Keuss, S. E., Harris, M., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12434 · Cited by 28
“We hypothesize two potential sources of variation that could be contributing to the differences between datasets: (1) the method of image acquisition or reconstruction and (2) the biological characteristics of the cohorts.”
Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
Boyarko, B., Podvin, S., Greenberg, B., Momper, J. D., Huang, Y., Gerwick, W. H., Bang, A. G., Quinti, L., Griciuc, A., Kim, D. Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190402 · Cited by 25
“Donanemab is an IgG1 antibody directed to an N-terminal pyroglutamate Aβ epitope and its evaluation in late stage clinical trials found that it improved cognition and lowered amyloid (Mintun et al., 2021).”
BackgroundMonoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease
Barrera-Ocampo, A. A. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.034 · Cited by 32
“Additional results showed that the treatment decreased the aggregation rate of NFT in the frontal cortex and other brain areas 166 .”
ResultCurrent peptide vaccine and immunotherapy approaches against Alzheimer’s disease
Parrocha, C. M. T., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24289 · Cited by 24
Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging
Macedo, A. C., Therriault, J., Tissot, C., Arias, J. F., Ferreira, P. C. L., Vitali, P., Servaes, S., Rahmouni, N., Vermeiren, M. R., Bezgin, G., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae043 · Cited by 26
“34,35 Here, we indicate that functionality might be a useful outcome in trials targeting participants at advanced but not early stages of tau accumulation.”
Terao, I., & Kodama, W. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230911 · Cited by 28
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 31
Performance Assessment of ChatGPT versus Bard in Detecting Alzheimer’s Dementia
Balamurali, B. T., & Chen, J. (2024) · Diagnostics · doi:10.3390/diagnostics14080817 · Cited by 37
Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 31
“Early results in targeting τ are promising in mice, but its therapeutic efficacy in humans has not yet been studied [51].”
BackgroundCalcium signaling hypothesis: A non-negligible pathogenesis in Alzheimer’s disease
Wang, M., Zhang, H., Liang, J., Huang, J., Wu, T., & Chen, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.01.007 · Cited by 35
“Although clinical trials of antibodies based on this hypothesis have made significant progress in recent years, concerns remain about the safety of these drugs [4,5].”
Afrin, M. R., Upadhyaya, P. G., Hashim, A., Bhattacharya, K., Chanu, N. R., Das, D., Khanal, P., & Deka, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102736 · Cited by 28
Wang, H., Nery, E. S. M., Ardayfio, P. A., Khanna, R., Svaldi, D. O., Shcherbinin, S., Xu, W., Andersen, S. W., Hauck, P. M., Brooks, D. A., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100266 · Cited by 31
“As ARIA-E is more likely to occur within 6 months after donanemab initiation, the timing and dosage of initial infusions are important considerations in ARIA-E reduction [ 1–3 ].”
Self-citationA manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 32
Body-wide multi-omic counteraction of aging with GLP-1R agonism
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Chan, R. C. H., Chan, D. T.-M., Wang, Z., Zheng, X., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.014 · Cited by 37
Peptides Derived from Growth Factors to Treat Alzheimer’s Disease
Gascon, S., Jann, J., Langlois-Blais, C., Plourde, M., Lavoie, C. L., & Faucheux, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116071 · Cited by 25
“However, a recent phase 2 trial of Donanemab, a humanized IgG1 antibody that targets a modified form of Aβ present only in established plaques, showed modest inhibition of cognitive and functional decline in early symptomatic AD patients [32].”
BackgroundBouter, Y., Liekefeld, H., Pichlo, S., Westhoff, A. C., Fenn, L., Bakrania, P., & Bayer, T. A. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02418-3 · Cited by 27
“ARIA-E has been reported in a small group of AD patients treated with donanemab, which could be a consequence of the lower plaque binding activity [8].”
BackgroundGeerts, H., Walker, M., Rose, R., Bergeler, S., van der Graaf, P. H., Schuck, E. L., Koyama, A., Yasuda, S., Hussein, Z., Reyderman, L., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12912 · Cited by 29
Amano, A., Sanjo, N., Araki, W., Anraku, Y., Nakakido, M., Matsubara, E., Tomiyama, T., Nagata, T., Tsumoto, K., Kataoka, K., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01772-y · Cited by 29
“Conversely, the N3pE Aβ-specific antibody mE8 (donanemab) reportedly improves cognitive functions in patients with early AD [24, 25] and removes existing Aβ plaques [24].”
BackgroundInflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Garmendia, J. V., Sanctis, C. V. D., Das, V., Annadurai, N., Hajdúch, M., & Sanctis, J. B. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231017141636 · Cited by 30
Matthews, D. C., Kinney, J. W., Ritter, A. R., Andrews, R. D., Strom, E. N. T., Lukic, A. S., Koenig, L. N., Revta, C., Fillit, H. M., Zhong, K., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12490 · Cited by 32
“35 For cross-correlation heat maps, plasma variables with a coefficient of variation (standard deviation/mean) greater than 20% after log10 transformation were excluded.”
Panwar, S., Uniyal, P., Kukreti, N., Hashmi, A., Verma, S., Arya, A., & Joshi, G. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14515 · Cited by 26
“However, the downregulation of PICALM leads to the reduction of APP and the generation of A β plaques (Mintun et al., 2021; Scheltens et al., 2021).”
BackgroundWang, G., Cutter, G., Oxtoby, N. P., Shan, G., Wang, W., Mangal, B., Liao, Y., Llibre‐Guerra, J. J., Li, Y., Xiong, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14035 · Cited by 20
“3,16 They could lead to longer estimated time savings using the BPP method and shorter estimates with other methods.”
Grill, J. D., Tam, S. P., Thai, G. T., Vides, B., Pierce, A. L., Green, K. N., Gillen, D. L., Teng, E., Kremen, S. A., Beigi, M., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000210152 · Cited by 26
McGeachan, R. I., Meftah, S., Taylor, L. W., Catterson, J. H., Negro, D., Bonthron, C., Holt, K., Tulloch, J., Rose, J. L., Gobbo, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58879-z · Cited by 26
An, S., McInnis, J. J., Kim, D., Li, Y., Tasdemir-Yilmaz, O. E., Ahn, J.-H., Mackness, B. C., Kwon, S., Bonner, J. M., Yoo, M., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01117-6 · Cited by 25
“…has been much more limited, the impact of antibody-based treatments in multiple sclerosis 12 – 14 and the very recent advances in antibodies targeting amyloid beta for the treatment of Alzheimer ’ s disease demonstrate the untapped potential for this modality in an area of great unmet need 15,16 .”
Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs
Teng, F., Liu, J., Cui, T., Tan, X., Liu, K., Hou, Z., (54356), L. Z., Xie, Y., Li, R., Li, D., et al. (2026) · Cell · doi:10.1016/j.cell.2026.01.034 · Cited by 31
What have we learned from past failures of investigational drugs for Alzheimer’s disease?
Imbimbo, B. P., & Watling, M. I. L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2017881 · Cited by 26
“However, there is also no correlation between brain Aβ plaque reduction and clinical effect with donanemab (r = −0.09, p = 0.244) [26].”
BackgroundInfluentialA Diagnostic Model for Alzheimer’s Disease Based on Blood Levels of Autophagy-Related Genes
Qin, Q., Gu, Z., Li, F., Pan, Y., Zhang, T., Yang, F., & Zhang, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.881890 · Cited by 26
Grossmann, K. (2022) · Biomedicines · doi:10.3390/biomedicines10081890 · Cited by 26
“Moreover, further antiAß antibodies, such as donanemab, gantenerumab, lecanemab, and solanezumab, which target Aß aggregation, fibril elongation, or plaque nucleation, are currently under clinical observation [2,7,30,44].”
BackgroundPrognostic and Predictive Factors in Early Alzheimer’s Disease: A Systematic Review
Garcia, M. J., Leadley, R. M., Ross, J., Bozeat, S., Redhead, G., Hansson, O., Iwatsubo, T., Villain, N., & Cummings, J. L. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230045 · Cited by 56
“[9].”
BackgroundInfluentialDonanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
Lenzer, J., & Brownlee, S. (2024) · BMJ · doi:10.1136/bmj.q2010 · Cited by 26
Mechanistic insights into procyanidins as therapies for Alzheimer's disease: A review
Ruan, W., Shen, S.-H., Xu, Y., Ran, N., & Zhang, H. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104683 · Cited by 23
Fessel, J. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12242 · Cited by 26
Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Beshir, S. A., Hussain, N., Menon, V. B., Haddad, A. H. I. A., Zeer, R. A. K. A., & Elnour, A. A. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/2052142 · Cited by 44
“Patients receiving donane-mab demonstrated a superior composite score for cognition and daily living activities (iADRS) at 76 weeks compared with those receiving placebo [72].”
BackgroundAljuhani, M., Ashraf, A., & Edison, P. (2024) · Brain Communications · doi:10.1093/braincomms/fcae435 · Cited by 26
Ye, B. S., Chang, K. W., Kang, S., Jeon, S., & Chang, J. W. (2025) · Journal of Neurosurgery · doi:10.3171/2024.8.jns24989 · Cited by 22
Nrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease
Soni, P., Sharma, S. M., Pieper, A. A., Paul, B. D., & Thomas, B. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00586 · Cited by 25
“Monoclonal antibodies, such as Aducanumab, Lecanemab, Donanemab, and Gantenerumab, have been developed to bind and remove A β deposits in the brain [71 – 75].”
González‐Escalante, A., Milà‐Alomà, M., Brum, W. S., Ashton, N. J., Ortiz-Romero, P. L., Shekari, M., del Campo, M., Anastasi, F., Quijano‐Rubio, C., Kollmorgen, G., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105741 · Cited by 33
“Remarkably, plasma p-tau217 and GFAP responded to anti-A β drugs in both the TRAILBLAZER-ALZ trial, 64 and in the Clarity AD trial 65 (together with plasma A β 42/40 and p-tau181).”
Ambient Air Pollution and the Severity of Alzheimer Disease Neuropathology
Kim, B., Blam, K., Elser, H. C., Xie, S. X., Deerlin, V. M. V., Penning, T. M., Weintraub, D. A., Irwin, D. J., Massimo, L. M., McMillan, C. T., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.3316 · Cited by 27
Abushakra, S. R., Power, A., Watson, D., Porsteinsson, A. P., Sabbagh, M., MacSweeney, E., Cohen, S., Boada, M., Doraiswamy, P. M., Liang, E., et al. (2025) · Drugs · doi:10.1007/s40265-025-02250-5 · Cited by 33
“Both drugs trigger microglial-mediated clearance of Aβ plaque and, to variable degrees, soluble Aβ protofibrils (large oligomers) [10, 29, 30].”
Wang, D., Kowalewski, E. K., & Koch, G. G. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00390-4 · Cited by 23
“Research and clinical studies on Aβ removal and its potential for slowing the progression of cognitive and functional decline in patients with Alzheimer’s disease has led to the development of multiple disease-modifying therapies, including monoclonal antibodies directed to bind and remove Aβ plaques in the brain, suc…”
BackgroundTogher, Z., Dolphin, H., Russell, C., Ryan, M., Kennelly, S., & O’Dowd, S. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5789 · Cited by 21
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Alavi, A. A., Satyamurthy, N., & Barrio, J. R. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220841 · Cited by 22
“Without any PET image documentation to support imaging signal decreases with an apparent dose-dependent decrease in amyloid deposits, therapeutic results would be inconclusive and unconvincing [13, 14].”
BackgroundChen, C. D., McCullough, A. A., Gordon, B. A., Joseph‐Mathurin, N., Flores, S. E., McKay, N. S., Hobbs, D. A., Hornbeck, R. C., Fagan, A. M., Cruchaga, C., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06209-0 · Cited by 25
“11C-PiB has been used in prior trials of bapineuzumab [2] and ponezumab [3], and 18F-florbetapir has been used in prior trials of aducanumab [4], crenezumab [2], donanemab [5], gantenerumab [6], lecanemab [7], and solanezumab [8] (Table 1).”
MethodSelf-citationEsquer, A., Blanc, F., & Collongues, N. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00541-1 · Cited by 27
“In this trial, between 72.5 and 74.2% of patients were APOE4 carriers, 19% and 22% of them being homozygous [40].”
BackgroundInfluentialInhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice
Qian, Z., Li, B., Meng, X., Liao, J., Wang, G., Li, Y., Luo, Q., & Ye, K. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01774-2 · Cited by 24
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Park, K. W. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00848-3 · Cited by 26
Zinc utilization by microglia in Alzheimer’s disease
Shippy, D. C., Oliai, S. F., & Ulland, T. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107306 · Cited by 28
“Two other anti-A b antibody therapies, lecanemab and donanemab have recently been approved and appear more ef fi cacious than aducanumab (204 – 207).”
Background
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.